ERBB2 and neoplasm: This may be because there was a significant heterogeneity in HER2 staining between xenograft tumor areas and the dose of trastuzumab used in this study was lower than in previously reported xenograft experiments [31], which may affect the amount of HER2 downregulation and assessment [32].